Merck will pay NGM Biopharmaceuticals $95 million and buy a 15% equity stake for $106 million as part of a five-year collaboration to develop diabetes and obesity treatments.
Merck will pay NGM Biopharmaceuticals $95 million and buy a 15% equity stake for $106 million as part of a five-year collaboration to develop diabetes and obesity treatments.